Spironolactone in Black / African Ancestry Patients: Documented Efficacy Gaps and What the Evidence Actually Shows

Why Ancestry Matters for Spironolactone Prescribing

Spironolactone is not a one-size-fits-all molecule. It competes with aldosterone at the mineralocorticoid receptor, blocks androgen receptors at higher doses, and is metabolized to active metabolites including canrenone and 7-alpha-thiomethylspironolactone. Each of those steps can differ by ancestry because of population-level differences in receptor genetics, aldosterone physiology, and renal function baseline.

For acne, most published trials enrolled predominantly white or unspecified populations. Layton and colleagues (Br J Dermatol 2017) reviewed the available evidence base for spironolactone in acne and noted that high-quality, prospective, randomized data remained limited, with no substantive ethnicity-stratified subgroup reporting [1]. That gap has not been closed since.

The Aldosterone Physiology Difference

Black individuals, on average, show lower plasma renin activity and relatively higher aldosterone concentrations compared to white individuals at equivalent blood pressures. This low-renin, salt-sensitive hypertension phenotype is well-documented [2]. For a drug whose mechanism depends on competing with endogenous aldosterone, a higher ambient aldosterone level could theoretically require higher doses to achieve the same receptor occupancy.

The data from hypertension trials support this concept. In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT, N=33,357), ACE inhibitors were less effective at lowering blood pressure in Black participants compared to calcium channel blockers or thiazide diuretics, partly because of the low-renin state [3]. Spironolactone is a mineralocorticoid receptor antagonist rather than a renin-angiotensin agent, but the same aldosterone-excess physiology is relevant to its binding dynamics.

What This Means for Acne Dosing

For acne, spironolactone's anti-androgenic effect begins at around 50 mg daily and approaches a ceiling near 200 mg daily. Most dermatologists start at 50 to 100 mg. If aldosterone receptor saturation requires higher drug concentrations in patients with elevated endogenous aldosterone, the 50 mg starting dose may be less effective in Black patients with low-renin physiology, even before pharmacogenomics enters the picture. This is mechanistic reasoning, not confirmed RCT data, and the distinction matters.

Pharmacogenomic Field for Spironolactone

Spironolactone's pharmacogenomic profile is genuinely underdeveloped. PharmGKB (the Pharmacogenomics Knowledgebase at Stanford) does not carry a Tier 1 or Tier 2 annotation for spironolactone metabolism variants in any ancestry group as of early 2025 [4].

CYP450 Metabolism and Ancestry Variants

Spironolactone undergoes rapid hepatic metabolism, primarily via CYP3A4. CYP3A4 activity varies considerably across individuals, but the *22 loss-of-function variant (rs35599367) that reduces CYP3A4 expression is found at a frequency of roughly 5-7% in European ancestry populations and may differ in African ancestry populations, though large African ancestry-specific CYP3A4 frequency data remain incomplete [5].

Canrenone, the principal active metabolite, has a half-life of 13 to 24 hours. Reduced CYP3A4 activity would slow conversion and increase parent drug exposure. Higher parent drug exposure could amplify both anti-androgenic effects and progestogenic side effects.

CYP11B2 (Aldosterone Synthase) Polymorphisms

The CYP11B2 gene encodes aldosterone synthase. The -344C/T promoter polymorphism (rs1799998) influences aldosterone production. The T allele is associated with higher aldosterone synthase expression and elevated aldosterone levels. Published frequency data show the T allele appears at different rates across ancestries, with some African ancestry cohorts showing higher T-allele frequencies, though estimates vary by the specific population studied [6]. Higher endogenous aldosterone production, driven by the T allele, could reduce spironolactone's effective concentration at the receptor.

Mineralocorticoid Receptor (NR3C2) Variants

The mineralocorticoid receptor gene NR3C2 carries several variants with ancestry-level frequency differences. The I180V variant (rs5522) modifies receptor sensitivity. Population pharmacogenomic databases including the 1000 Genomes Project show allele frequency differences between African superpopulation samples and European superpopulation samples for NR3C2 variants, though clinical translation for acne outcomes has not been studied in controlled settings [7].

The Evidence Gap in Acne-Specific Trials

The acne literature on spironolactone is growing but remains ethnicity-blind in most published work.

What SADA and Other Trials Actually Reported

The SADA trial (Spironolactone for Adult Female Acne, BMJ 2023, N=410) was the largest placebo-controlled RCT of spironolactone for acne to date. It showed a meaningful reduction in acne at 24 weeks with spironolactone 50 to 150 mg daily, but the published results did not include ethnicity-stratified outcomes [8]. The baseline demographic table in SADA showed that the enrolled population was predominantly white British, which limits generalizability to Black and African ancestry patients.

Layton et al.'s 2017 systematic review, the reference standard for evidence-grading spironolactone in acne, likewise found no studies with ethnicity-specific acne response data [1]. That remains the status as of this writing.

Observational and Retrospective Data

Retrospective chart reviews from U.S. Dermatology practices occasionally include race as a covariate. A 2019 retrospective cohort from a U.S. Academic center found that Black women were less likely to be prescribed spironolactone for acne than white women with comparable severity scores, after adjusting for insurance status and comorbidities [9]. That disparity in prescribing is a separate problem from pharmacodynamic differences, but the two can compound each other: a population that is underprescribed a drug is also underrepresented in the outcome data, making efficacy gaps harder to detect.

Post-Inflammatory Hyperpigmentation as an Endpoint

For Black patients with acne, the outcome that matters most is frequently not lesion count alone. Post-inflammatory hyperpigmentation (PIH) is a major driver of treatment-seeking in patients with Fitzpatrick skin types IV through VI. Spironolactone reduces new inflammatory lesion formation, which should in theory reduce PIH incidence. No trial has used PIH resolution as a primary endpoint in a spironolactone study, and no trial has included a sufficient number of darker-skinned patients to power a subgroup analysis on this outcome.

Hyperkalemia, Renal Function, and Heightened Monitoring Needs

Black Americans carry a disproportionately high burden of chronic kidney disease. The Centers for Disease Control reports that Black adults are approximately 3 times more likely to develop kidney failure than white adults [10]. CKD reduces potassium clearance. Spironolactone blocks aldosterone-mediated renal potassium excretion.

Baseline CKD Prevalence Changes the Risk Calculus

At an estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73m², hyperkalemia risk with spironolactone rises sharply. Standard dermatology prescribing guidelines suggest potassium monitoring only for patients with diabetes, renal impairment, or those on ACE inhibitors or ARBs. Given higher baseline CKD rates, a larger fraction of Black patients will fall into the monitoring-required category than the average clinic population.

The American Academy of Dermatology's acne guidelines acknowledge that hyperkalemia risk should prompt individualized monitoring, but do not specify ethnicity-based monitoring protocols [11].

Practical Monitoring Protocol

A basic metabolic panel (BMP) at baseline, then at 4 weeks after starting or dose-escalating spironolactone, catches most clinically significant potassium rises before they become dangerous. For patients with eGFR <60 mL/min/1.73m², monthly monitoring for the first three months is a more conservative and defensible approach.

G6PD Deficiency: An Underappreciated Safety Consideration

G6PD deficiency affects an estimated 10 to 14% of African ancestry males and a smaller but non-trivial proportion of females [12]. Spironolactone's oxidative metabolite pathway is not among the classic triggers of G6PD-related hemolysis (such as primaquine or dapsone), and no case series specifically linking spironolactone to hemolytic episodes in G6PD-deficient patients has been published. The mechanistic concern is that spironolactone is metabolized to reactive thiomethyl intermediates that could, theoretically, generate oxidative stress.

The absence of case reports here is partly absence of evidence rather than evidence of absence. G6PD testing before spironolactone is not standard of care and is not recommended in current guidelines. Clinicians should be aware of the gap.

Cardiovascular Trial Subgroup Data: Lessons from Hypertension Research

The PATHWAY-2 trial (N=335) established spironolactone as the most effective add-on antihypertensive for resistant hypertension, but its sample was not large enough for meaningful ethnicity subgroup analysis [13]. The EMPHASIS-HF trial of eplerenone (a selective mineralocorticoid receptor antagonist chemically related to spironolactone) in heart failure included a modest proportion of Black patients, and no significant heterogeneity of treatment effect by race was observed, though the subgroup was underpowered [14].

The closest proxy data come from the RALES trial (N=1,663), which showed that spironolactone 25 mg reduced all-cause mortality by 30% in severe heart failure. Race-stratified data were not reported in the primary publication [15]. These cardiovascular trials were not designed to answer the acne dosing question, but they represent the only controlled trial data touching on spironolactone response across different population groups, and their silence on ethnicity subgroups is informative about the overall evidence gap.

Anti-Androgen Physiology and Testosterone Differences by Ancestry

Androgens drive acne by stimulating sebaceous gland activity and follicular hyperkeratinization. Spironolactone blocks androgen receptors and inhibits 5-alpha-reductase activity. Whether androgen levels or androgen receptor sensitivity differ systematically by ancestry in women with acne has not been rigorously studied.

Androgen Receptor CAG Repeat Length

The androgen receptor gene (AR) contains a polymorphic CAG trinucleotide repeat in exon 1. Shorter CAG repeats correlate with greater receptor transcriptional activity. Published data from the 1000 Genomes Project and population-specific cohorts show that mean CAG repeat length differs modestly between African and European ancestry groups, with African ancestry populations carrying somewhat shorter mean repeat lengths [16]. Shorter repeat length means more androgen receptor activity per unit of androgen, which could mean more androgen-driven sebum production and a higher spironolactone dose needed to suppress it.

This remains an area of active pharmacogenomic research and has not been translated into clinical dosing recommendations.

Sebaceous Gland Density and Sebum Production

Skin biology itself may differ. Some small studies suggest sebum production rates differ across Fitzpatrick skin types, though the data are not consistent across measurement methods [17]. If baseline sebum output differs, the amount of androgen receptor blockade needed to normalize it may also differ.

Clinical Decision-Making: A Practical Framework for Black Patients

Given the evidence gaps, how should a clinician approach spironolactone prescribing for a Black or African ancestry patient with hormonal acne?

Step 1. Assess Renal and Electrolyte Baseline

Order a BMP before the first prescription. Calculate or estimate eGFR. If eGFR <45 mL/min/1.73m², spironolactone should be used with caution and endocrinology or nephrology input is reasonable.

Step 2. Start at 50 mg, Titrate Based on Response

The standard 50 mg starting dose is appropriate. Monitor lesion count and sebum-related symptoms at 8 to 12 weeks. The mechanistic rationale for potentially needing higher doses (based on aldosterone physiology) does not override the principle of starting low and titrating up. Push to 100 mg at 12 weeks if response is partial and tolerability is good.

Step 3. Recheck Potassium at 4 Weeks

For any Black patient with diabetes, hypertension, or eGFR <60 mL/min/1.73m², a 4-week BMP recheck is the appropriate safety net.

Step 4. Track PIH Separately

Use a validated PIH grading tool such as the Postinflammatory Hyperpigmentation Scale or physician global assessment of dyspigmentation alongside standard acne severity scoring. This documents benefit on the outcome that matters most to many patients with darker skin tones.

Step 5. Document Ancestry in the Chart and in Outcomes

Individual practices that track response by ancestry contribute to the aggregate evidence base. A shared registry approach across HealthRX-affiliated providers is the mechanism most likely to generate the ethnicity-stratified data the field currently lacks.

What Guidelines Say (and Don't Say)

The American Academy of Dermatology 2016 acne guidelines, updated with supplementary recommendations in subsequent years, mention spironolactone as an option for females with hormonal acne. They do not include ethnicity-specific dosing or monitoring recommendations [11].

The Endocrine Society's clinical practice guideline on androgen excess in women also does not stratify spironolactone recommendations by ancestry [18]. As the guideline document states, "spironolactone at doses of 100 to 200 mg/day is effective for hyperandrogenic symptoms," without qualification by patient ancestry.

That absence is not a clinical endorsement of uniform response across all populations. The guidelines reflect the populations actually enrolled in the trials that informed them.